Compile Data Set for Download or QSAR
Report error Found 867 Enz. Inhib. hit(s) with all data for entry = 9953
TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM502821(trans-4-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)pyr...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325424((S)-3-(4-(4-(1-((S)- pentan-2-yl)-1H-pyrazol- 4-yl...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325374(2-amino-1-(4-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-y...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325423((R)-2-(4-(4-(1-(sec- butyl)-1H-pyrazol-4- yl)pyraz...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325470(US10189845, Example 133B | US10189845, Example 132...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325374(2-amino-1-(4-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-y...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325372(N-methyl-4-(4-(4-(1- (pentan-3-yl)-1H-pyrazol- 4-y...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM502874((1s,3s)-1-(hydroxymethyl)-3-(4-(4-(1-(pentan-3-yl)...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325371(2-methoxy-1-(4-(4-(4-(1- (pentan-3-yl)-1H-pyrazol-...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325371(2-methoxy-1-(4-(4-(4-(1- (pentan-3-yl)-1H-pyrazol-...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM502873((1s,3 s)-1-methyl-3-(4-(4-(1-(pentan-3-yl)-1H-pyra...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325370(6-(1-(1- (methylsulfonyl)piperidin- 4-yl)-1H-pyraz...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325370(6-(1-(1- (methylsulfonyl)piperidin- 4-yl)-1H-pyraz...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325515((1- hydroxycyclopropyl)(3- (4-(4-(1-(pentan-3-yl)-...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325369(1-(4-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)pyrazo...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325386(4-(1-(3-ethyl-1-((trifluoromethyl)sulfonyl)azetidi...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325386(4-(1-(3-ethyl-1-((trifluoromethyl)sulfonyl)azetidi...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325514(2-hydroxy-2-methyl-1-(3- (4-(4-(1-(pentan-3-yl)- 1...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325545(US10189845, Example 207A | US10730880, Example 207...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325457(cis-3-(4-(4-(1-(pentan-3- yl)-1H-pyrazol-4- yl)pyr...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325351(3-(4-(4-(1-(pentan-3-yl)-1H- pyrazol-4-yl)pyrazolo...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325375(6-(1-(1-(methylsulfonyl)azetidin-3-yl)-1H-pyrazol-...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325553(US10189845, Example 215B | US10730880, Example 215...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325553(US10189845, Example 215B | US10730880, Example 215...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325422((S)-2-(4-(4-(1-(sec- butyl)-1H-pyrazol-4- yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM325422((S)-2-(4-(4-(1-(sec- butyl)-1H-pyrazol-4- yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325422((S)-2-(4-(4-(1-(sec- butyl)-1H-pyrazol-4- yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325421((R)-2-(4-(4-(1-(pentan-2- yl)-1H-pyrazol-4- yl)pyr...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325421((R)-2-(4-(4-(1-(pentan-2- yl)-1H-pyrazol-4- yl)pyr...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455552(US10730880, Example 218 | (S)-1-(4-(4-(1-((R)-1-cy...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325420((S)-2-(4-(4-(1-(pentan-2-yl)-1H-pyrazol-4-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455545(US10730880, Example 211 | US10730880, Example 212 ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325428(US10189845, Example 90B | US10730880, Example 90 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455545(US10730880, Example 211 | US10730880, Example 212 ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325427(US10189845, Example 89A | US10730880, Example 89 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325427(US10189845, Example 89A | US10730880, Example 89 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325551(US10189845, Example 214A | US10189845, Example 213...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325551(US10189845, Example 214A | US10189845, Example 213...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325551(US10189845, Example 214A | US10189845, Example 213...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325424((S)-3-(4-(4-(1-((S)- pentan-2-yl)-1H-pyrazol- 4-yl...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325430(US10189845, Example 92B | US10730880, Example 92 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325430(US10189845, Example 92B | US10730880, Example 92 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325429(US10189845, Example 91A | US10730880, Example 91 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325429(US10189845, Example 91A | US10730880, Example 91 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325428(US10189845, Example 90B | US10730880, Example 90 |...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325436(1-amino-3-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)p...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325436(1-amino-3-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)p...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

Displayed 1 to 50 (of 867 total ) | Next | Last >>
Jump to: